042sek
-7,3 %
Date:2025-05-14Time:17:17:52Latest report:Q4-2024List:First NorthTicker:XINT
Market Cap:278 msekEnterprise Value:261 msekNet Sales:4,22 msekEarnings:-39,9 msekEmployees:0ISIN:SE0007756903

Ratios

10-year key figure history for Xintela turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Xintela with index and moving average MA50 and MA200.

Stockprice:0,42
MA50:0,41
MA200:0,40
Price/MA200:3,3 %
RSI (14):57,0
Price/MA50:2,1 %

Description

Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Biotechnology